Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8388MR)

This product GTTS-WQ8388MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8388MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5691MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ3567MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ986MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ302MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ3291MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ12246MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ15135MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ13879MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-1979
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW